Selected article for: "action main mechanism and main mechanism"
Author: Primorac, Dragan; Čemerin, Martin; Matišić, Vid; Molnar, Vilim; Strbad, Marko; Girandon, Lenart; Zenić, Lucija; Knežević, Miomir; Minger, Stephen; Polančec, Denis
Title: Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
  • Cord-id: glhukxw2
  • Document date: 2021_9_16
    • ID: glhukxw2
    Snippet: The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID-19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indication
    Document: The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID-19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indications for over a decade, with a safe side effect profile and promising results in preclinical and clinical trials. Therefore, the use of MSCs in COVID-19-induced respiratory failure and ARDS was a logical step in order to find a potential treatment option for the most severe patients. In this review, the main characteristics of MSCs, their proposed mechanism of action in COVID-19 treatment and the effect of this therapy in published case reports and clinical trials are discussed.

    Search related documents:
    Co phrase search for related documents
    • abnormal chest and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • abnormal chest and lung damage: 1
    • abnormal chest and lung function: 1, 2, 3, 4, 5, 6
    • abnormal chest and lung infiltrate: 1, 2
    • abnormal chest and lung inflammation: 1
    • abnormal chest and lung injury: 1, 2
    • abnormal chest and lung parenchyma: 1, 2, 3, 4
    • abnormal chest and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • abnormal chest imaging and acute ards respiratory distress syndrome: 1
    • abnormal chest imaging and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • abnormal chest imaging and lung function: 1, 2
    • abnormal chest imaging and lung infiltrate: 1
    • abnormal chest imaging and lung injury: 1
    • abnormal chest imaging and lymphocyte count: 1, 2
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and low absent: 1
    • acute ards respiratory distress syndrome and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11